CD4(+)CD25(+) T Cells in primary malignant hypertension related kidney injury.
CD4(+)CD25(+) T cells are critical for maintenance of immunologic self-tolerance. We measured the number of CD4(+)CD25(+) cells in the patients with primary malignant hypertension related kidney injury, to explore the molecular pathogenesis of this disease. We selected 30 patients with primary malignant hypertension related kidney injury and 30 healthy volunteers. Information on clinical characteristics and laboratory tests was obtained from each subject. The number of CD4(+)CD25(+) cells and glomerular injury were assessed by flow cytometry and histopathology, respectively. Both serum IL-2, IL-4, and IL-6 and endothelial cell markers were analyzed by ELISA. ADAMTS13 antibody was detected by Western blotting. CD4(+)CD25(+) cells were significantly reduced in patients with primary malignant hypertension related kidney injury compared to controls (P < 0.05). The number of CD4(+)CD25(+) cells was negatively related to blood urea nitrogen, serum uric acid, proteinuria, and supernatant IL-4; whereas positively associated with estimated glomerular filtration rate in patients. Gradually decreasing CD4(+)CD25(+) cells were also found as increasing renal injury. Additionally, patients exhibited increasing supernatant IL-4, serum IL-2 and IL-6, endothelial cell markers, and anti-ADAMTS13 antibody compared with controls (all P < 0.05). CD4(+)CD25(+) cells may play a key role in the pathogenesis of primary malignant hypertension related kidney injury.
Division of Nephrology, Beijing Shijitan Hospital, Capital Medical University, The 9th Affiliated Hospital of Peking University, Beijing, P.R. China.|Division of Nephrology, Hunan Normal University, Hunan Provincial People's Hospital of China, Changsha, Hunan Province, P.R. China.
Hongdong
H
Huang
Division of Nephrology, Beijing Shijitan Hospital, Capital Medical University, The 9th Affiliated Hospital of Peking University, Beijing, P.R. China.
Yang
Y
Luo
Division of Nephrology, Hunan Normal University, Hunan Provincial People's Hospital of China, Changsha, Hunan Province, P.R. China.
Yumei
Y
Liang
Department of Liver Surgery, the Affiliated Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China.
Xidai
X
Long
Hunan Key Laboratory of Nephrology and Hemoperfusion, Division of Nephrology, Second Xiangya Hospital of Central South University, Changsha, Hunan Province, P.R. China.
Youming
Y
Peng
Division of Nephrology, Beijing Shijitan Hospital, Capital Medical University, The 9th Affiliated Hospital of Peking University, Beijing, P.R. China.
Zhihua
Z
Liu
Division of Nephrology, Beijing Shijitan Hospital, Capital Medical University, The 9th Affiliated Hospital of Peking University, Beijing, P.R. China.
Xiaojun
X
Wen
Division of Nephrology, Beijing Shijitan Hospital, Capital Medical University, The 9th Affiliated Hospital of Peking University, Beijing, P.R. China.
Meng
M
Jia
Division of Nephrology, Beijing Shijitan Hospital, Capital Medical University, The 9th Affiliated Hospital of Peking University, Beijing, P.R. China.
Ru
R
Tian
Division of Nephrology, Beijing Shijitan Hospital, Capital Medical University, The 9th Affiliated Hospital of Peking University, Beijing, P.R. China.
Chengli
C
Bai
Division of Nephrology, Beijing Shijitan Hospital, Capital Medical University, The 9th Affiliated Hospital of Peking University, Beijing, P.R. China.
Cui
C
Li
Department of Interventional Therapy, Beijing Shijitan Hospital, Capital Medical University, The 9th Affiliated Hospital of Peking University, Beijing, P.R. China.|Section of Hematology/Oncology, Section of Gastroenterology, Stephenson Cancer Center, Department of Internal Medicine, College of Medicine, The University of Oklahoma Health Sciences Center, USA.
Fuliang
F
He
Section of Hematology/Oncology, Section of Gastroenterology, Stephenson Cancer Center, Department of Internal Medicine, College of Medicine, The University of Oklahoma Health Sciences Center, USA.
Qiushi
Q
Lin
Center of Allergy, Beijing Shijitan Hospital, Capital Medical University, Beijing, P.R. China.
Xueyan
X
Wang
Department of Interventional Therapy, Beijing Shijitan Hospital, Capital Medical University, The 9th Affiliated Hospital of Peking University, Beijing, P.R. China.|Section of Hematology/Oncology, Section of Gastroenterology, Stephenson Cancer Center, Department of Internal Medicine, College of Medicine, The University of Oklahoma Health Sciences Center, USA.
Xiaoqun
X
Dong
D000071120:ADAMTS13 Protein / Q000097:blood; D000328:Adult; D015496:CD4-Positive T-Lymphocytes / Q000378:metabolism*; D016022:Case-Control Studies; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D006974:Hypertension, Malignant / Q000097:blood* / Q000150:complications; D053645:Interleukin-2 Receptor alpha Subunit / Q000235:genetics / Q000378:metabolism; D007378:Interleukins / Q000097:blood; D008297:Male; D008875:Middle Aged; D051437:Renal Insufficiency / Q000097:blood* / Q000209:etiology; D014527:Uric Acid / Q000097:blood
D053645:Interleukin-2 Receptor alpha Subunit; D007378:Interleukins; D014527:Uric Acid; D000071120:ADAMTS13 Protein; C099604:ADAMTS13 protein, human